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ABSTRACT
Introduction. Stenting is a widespread procedure for patients suffering from coronary artery disease. The 
use of drug-covered stents has improved stenting safety and treatment efficiency. Using second-genera-
tion Biolimus drug-covered A9 stents is associated with reduced risk of stent thrombosis compared with 
first-generation ones. The aim of the study was to evaluate two years’ treatment results after implantation 
of Biolimus A9 stents in coronary arteries in patients who suffer from coronary artery disease. 
Methods. The study included 216 patients who suffered from coronary artery disease and were treated 
using Biolimus A9 drug-covered stents, in order to eliminate all greater-than-50% stenoses. Patients’ data 
were collected from hospital case histories and e-Biomatrix PMR questionnaire. Decisions regarding 
whether to use Biolimus A9 stents during percutaneous coronary intervention were made by the respective 
operators. The rate of complication after stenting was evaluated when stenosis was eliminated or reduced 
to 30% or TIMI 3 flow was determined. 
Results. Out of 216 patients included in the study, 151 were males (69.91%) and 30.09% (65) were fe-
males. Mean of age of patients was 60.2 ± 10.1 years; 19% of patients had diagnosed diabetes. The 
success rate of implanting Biolimus A9 stents was 100% with no complications during hospital stay. 
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Introduction 
Stenting is a widespread procedure for patients 
suffering from coronary artery disease. The possibility 
of using drug-covered stents has improved stenting 
safety and treatment efficiency. The use of second-gen-
eration Biolimus drug-covered A9 stents is associated 
with reduced risk of stent thrombosis when compared 
with first-generation ones. Drug-eluting stents (DES) 
have greatly reduced the risk of restenosis compared 
with bare-metal stents and have become the standard 
of care for patients undergoing percutaneous coronary 
intervention (PCI). However, the durable polymer within 
the vessel is considered responsible for ongoing in-
flammation, leading to late complications such as stent 
thrombosis. From these innovations, the second-gener-
ation everolimus-eluting stent (EES) using a biocompat-
ible durable polymer (fluorinated copolymer) with thin 
strut (81 mm) and the third-generation biolimus-eluting 
stent (BES) using an abluminally coated biodegrad-
able polymer (polylactic acid) with relatively thick strut 
(112 mm) are currently considered the safest DESs. 
PCI is the preferred treatment for patients with acute 
myocardial infarction (AMI) [1, 2]. In both elective and 
primary PCIs, DES showed reduced restenosis rates 
compared with bare metal stents, but still it is not clear 
whether late restenosis is possible [3–6]. Because 
AMI is a predictor of thrombotic stent complications 
occurring late after DES implantation in the presence of 
a high thrombus burden, careful consideration of both 
the risks and benefits of DES is necessary, especially in 
the clinical practice for AMI patients [7, 8]. The biode-
gradable polymer BES (BioMatrix, Biosensors; Nobori, 
Terumo) is composed of stainless steel alloy and an 
abluminally-coated biodegradable polymer eluting Bi-
olimus A9, a highly lipophilic analogue of sirolimus. Use 
of second-generation Biolimus drug-covered A9 stents 
is associated with reduced risk of stent thrombosis com-
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pared with the first generation. Additionally, the high de-
gree of lipophilicity may provide a more potent local ef-
fect on lipid-rich plaques in lesions causing AMI [9, 10]. 
The goals of using a biodegradable polymer BES are 
to reduce the risk of late-onset thrombosis with non-in-
feriority with respect to target vessel revascularisation 
compared with other DESs. However, there are limited 
data regarding clinical outcomes of biodegradable 
polymer BES in subjects presenting with AMI and late 
stent thrombosis. The aim of this study was to evalu-
ate two-year treatment results after Biolimus A9 stent 
implantation in coronary arteries in patients who suffer 
from coronary artery disease.
Methods
Study population
A total of 216 patients who suffered from coronary 
artery disease were treated using Biolimus A9 drug-cov-
ered stents in order to eliminate all greater-than-50% ste-
noses. Patients’ data were collected from hospital case 
histories and e-Biomatrix PMR questionnaires. Con-
secutive patients with ST-segment elevation myocar-
dial infarction (STEMI) and non-ST segment elevation 
myocardial infarction (NSTEMI) underwent PCI using 
a BES. Decisions regarding whether to use a BES during 
PCI were made by the respective operators. The rate 
of complications after stenting was evaluated when 
stenoses were eliminated or reduced to 30% or TIMI 
3 flows were determined.
All procedures were performed using standard inter-
ventional techniques. Loading doses of aspirin (300 mg) 
and clopidogrel (300 or 600 mg) were administered 
unless patients had previously received antiplatelet 
medications for more than one week. The type of DES, 
use of glycoprotein IIb/IIIa receptor antagonists, PCI 
performed on non-culprit vessels, and the duration of 
clopidogrel therapy after PCI were at the discretion of 
the physician.
Definitions and measured outcomes
We assessed two study endpoints, two years after 
stent placement: an efficacy endpoint and a safety 
endpoint. The efficacy endpoint was defined by target 
vessel failure, which was a composite of cardiac death, 
target vessel-related myocardial infarction (MI), and 
target vessel revascularisation. The safety endpoint 
was a composite of all cause death, MI, and stent 
thrombosis. Clinical outcomes measured after two 
years were all-cause death, cardiac death, AMI, target 
lesion revascularisation, target vessel revascularisation, 
and stent thrombosis. MI was defined as elevated car-
diac biomarkers (troponin or CK-MB) with ischaemic 
symptoms or electrocardiographic findings indicative 
of ischaemia. Target lesion revascularisation was de-
fined as repeat PCI of the lesion within 5 mm of stent 
deployment or bypass graft of the target vessel. Target 
vessel revascularisation was defined as any percutane-
ous or surgical revascularisation of the treated target 
vessel. Stent thrombosis was described as definite or 
probable according to the definitions set forth by the 
Academic Research Consortium [11]. Baseline clinical, 
angiographic, and procedural findings were collected 
retrospectively, and clinical outcome data were record-
ed in the dedicated PCI registry by research personel.
Statistical analyses
Categorical variables were summarised as frequen-
cies with percentages and were compared using Chi-
square test or Fisher’s exact test. Survival curves were 
constructed using Kaplan–Meier estimates and were 
compared using log-rank test.
Results
Mean of age of 216 study patients was 60.2  ± 
± 10.1 years. 19% of patients had diabetes. The suc-
cess rate of implanting Biolimus A9 stents was 100%, 
with no complications whatsoever while the patients 
were in the hospital. After performing a follow-up on 
these patients, it was found that there were four cases 
with complications in the one-year period after stenting 
procedure. In one case of stent thrombosis was found, 
one patient suffered a stroke, and two patients need-
ed revascularisation afterwards, so the complication 
rate was 1.4%. During the second year period after 
stenting was performed, the patient follow-up showed 
a complication rate of only 0.46%; one case needed re-
vascularisation.
Discussion
The study of Biolimus A9 stents showed that they 
are highly effective with a relatively low complication 
rate. Therefore, they could be recommended for more 
frequent use. The biodegradable polymer BES is com-
posed of stainless steel alloy and an abluminally-coated 
biodegradable polymer eluting biolimus A9, a highly 
lipophilic analogue of sirolimus; the drug is rapidly ab-
sorbed by surrounding tissue. Subsequent degradation 
of the polymer on the surface of the stent may help to 
avoid late-onset thrombosis by reducing local hyper-
sensitivity reactions to the durable polymer [12, 13]. 
Additionally, the high degree of lipophilicity may provide 
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a more potent local effect on lipid-rich plaques in lesions 
causing acute myocardial infarction. The goal of using 
a biodegradable polymer BES are to reduce the risk of 
late-onset thrombosis with non-inferiority with respect 
to target vessel revascularisation compared with other 
DESs. The stent elutes biolimus (15.6 μg/mm) for up 
to 30 days. The coating design of the stent combined 
with the lipophilicity of the drug is thought to optimise 
local drug distribution and to reduce its release into 
the circulation. Biolimus inhibits proliferation of smooth 
muscle cells similarly to sirolimus. Moreover, biolimus 
may offer significant advantages compared with other 
“limus” agents because it may improve pharmacoki-
netics due to its high lipophilicity and, consequently, 
optimise bioavailability with rapid distribution into the 
arterial wall during the initial hours after stent implan-
tation; this allows achievement of faster therapeutic 
concentrations and extended duration of treatment ef-
fect, which may counterbalance the potentially negative 
effects of boost release.
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